ZYFLO CR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
May 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYFLO CR is an extended-release oral tablet approved in 2007 by Chiesi. The specific indication and mechanism of action are not provided in available data, limiting characterization of its therapeutic role.
LOE Approaching
Product approaching loss of exclusivity signals a contracting revenue base and likely reduced commercial team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for this product. Career opportunities are likely focused on transition planning, generic defense, and cost management rather than growth initiatives.
Brand ManagerField Sales
Worked on ZYFLO CR at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.